Renmin Hospital of Wuhan University

ICI-based treatments showed survival benefits for heavily pretreated MSS mCRC patients, with a median OS of 11.8 months and PFS of 4.6 months. ICI plus TKI combinations, with or without chemotherapy, demonstrated meaningful survival improvement, though liver metastasis negatively impacted prognosis. The study highlighted the efficacy and safety of ICI regimens in MSS mCRC.

PSC-CM research has advanced heart disease understanding, tissue engineering, and drug discovery. Bibliometric analysis (2007-2024) shows U.S. dominance, with Stanford University and Joseph C. Wu leading. Key research areas include organ-on-a-chip, 3D bio-printing, and cardiac organoids. Challenges in stem-cell-mediated therapies persist.

Researchers from Renmin Hospital and Yale University developed a plant-based nanoparticle treatment using bardoxolone methyl to target glioblastoma cells in mice, overcoming challenges of tumor cell killing and brain penetration, with minimal systemic toxicity.